Celldex Therapeutics, Inc. $CLDX Shares Purchased by Commodore Capital LP

Commodore Capital LP increased its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 5.1% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 2,696,616 shares of the biopharmaceutical company’s stock after acquiring an additional 131,616 shares during the quarter. Celldex Therapeutics makes up about 4.9% of Commodore Capital LP’s investment portfolio, making the stock its 7th largest position. Commodore Capital LP’s holdings in Celldex Therapeutics were worth $85,537,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Wellington Management Group LLP grew its holdings in Celldex Therapeutics by 39.3% in the 4th quarter. Wellington Management Group LLP now owns 8,079,608 shares of the biopharmaceutical company’s stock valued at $219,442,000 after buying an additional 2,279,605 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Celldex Therapeutics by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 4,027,407 shares of the biopharmaceutical company’s stock worth $109,384,000 after acquiring an additional 72,817 shares during the period. Bellevue Group AG raised its holdings in shares of Celldex Therapeutics by 7.6% during the 3rd quarter. Bellevue Group AG now owns 3,557,669 shares of the biopharmaceutical company’s stock worth $92,037,000 after acquiring an additional 250,100 shares during the period. State Street Corp boosted its position in shares of Celldex Therapeutics by 19.5% during the 4th quarter. State Street Corp now owns 3,397,713 shares of the biopharmaceutical company’s stock valued at $92,282,000 after acquiring an additional 555,579 shares during the last quarter. Finally, Braidwell LP boosted its position in shares of Celldex Therapeutics by 214.0% during the 4th quarter. Braidwell LP now owns 1,858,109 shares of the biopharmaceutical company’s stock valued at $50,466,000 after acquiring an additional 1,266,420 shares during the last quarter.

Celldex Therapeutics Price Performance

NASDAQ CLDX opened at $35.28 on Monday. The firm’s 50-day moving average is $33.64 and its two-hundred day moving average is $30.71. Celldex Therapeutics, Inc. has a 12 month low of $19.72 and a 12 month high of $40.30. The stock has a market capitalization of $2.77 billion, a P/E ratio of -8.28 and a beta of 0.90.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.80 million. As a group, analysts anticipate that Celldex Therapeutics, Inc. will post -4.36 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. UBS Group raised their price objective on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, June 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Friday, July 17th. HC Wainwright reiterated a “buy” rating and issued a $42.00 target price on shares of Celldex Therapeutics in a report on Monday, June 15th. Cantor Fitzgerald dropped their price target on shares of Celldex Therapeutics from $67.00 to $61.00 and set an “overweight” rating for the company in a research note on Wednesday, July 22nd. Finally, Wells Fargo & Company cut their price target on shares of Celldex Therapeutics from $54.00 to $48.00 and set an “overweight” rating for the company in a report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Celldex Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $52.77.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.